Search cutoffs
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Current report (Form 8-K) · Jun 11, 2026 · Multiple disclosures including leadership change and acquisition or asset sale
| ItemItem | Disclosure |
|---|---|
| Item 1.01 | Entered a material definitive agreement |
| Item 2.01 | Completed an acquisition or asset sale |
| Item 2.03 | Created a direct financial obligation |
| Item 3.02 | Item 3.02 |
| Item 5.02 | Director or executive officer departure or appointment |
| Item 5.03 | Amended articles of incorporation or bylaws |
| Item 7.01 | Regulation FD disclosure (investor press release or presentation) |
| Item 9.01 | Financial statements and exhibits |
ADIAL PHARMACEUTICALS, INC. filed this to disclose a change in directors or executive officers appointments, departures, or role changes that can signal a strategic shift.
htm PRESS RELEASE ISSUED ON JUNE 11, 2026 Exhibit 99. 1 Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing Acquisition of Azora and concurrent private placement positions the combined company to advance its pipeline through key clinical milestones in ulcerative colitis, including Phase 1 initiation in mid-2027 - Azora’s oral candidate, AT177, is a novel, colon - targeted AhR agonist rationally engineered to have minimal systemic exposure and designed to mitigate…
This filing reports Item 1.01 (entered a material definitive agreement); Item 2.01 (completed an acquisition or asset sale); Item 5.02 (director or executive officer departure or appointment). These item codes often precede or accompany restructuring, leadership changes, or deals that can shift headcount.
ADIAL PHARMACEUTICALS, INC. reported material events that can affect workforce planning. cutoffs surfaces the filing alongside WARN layoffs, H-1B activity, and company signals.
